Raises BRIUMVI U.S. net product revenue target to approximately $585 million for the full year 2025, prior guidance of $570 – $575 million for full year 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TG Therapeutics completes enrollment in Phase 3 ENHANCE trial
- TGTX Earnings this Week: How Will it Perform?
- TG Therapeutics’ New Study on Ublituximab: A Potential Game-Changer for Pediatric MS Treatment
- TG Therapeutics’ Phase 3 Study: A New Approach to Multiple Sclerosis Treatment
- TG Therapeutics’ Ublituximab Study: A Potential Game-Changer for RMS Treatment?